ProCE Banner Activity

Selecting Patients for PARP Inhibitor Therapy: Principles of Genetic Testing

Slideset Download
Learn how urologists can identify patients with metastatic prostate cancer most likely to benefit from PARP inhibitor therapy with these downloadable slides reviewing why, how, and when to perform genetic testing.

Released: October 17, 2022

Expiration: October 16, 2023

Share

Faculty

Stephen Freedland

Stephen Freedland, MD

Professor
Department of Surgery
Department of Urology
Cedars-Sinai Medical Center
Los Angeles, California
Staff Physician
Durham VA Medical Center
Durham, North Carolina

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Faculty Disclosure

Primary Author

Stephen Freedland, MD

Professor
Department of Surgery
Department of Urology
Cedars-Sinai Medical Center
Los Angeles, California
Staff Physician
Durham VA Medical Center
Durham, North Carolina

Stephen Freedland, MD: consultant/advisor/speaker: Astellas, AstraZeneca, Bayer, Janssen, Merck, Myovant, Pfizer, Sanofi.